Galectin-9, FABP4 and pentraxin-3 are associated with myocardial dysfunction and discriminate chemotherapy-related cardiac dysfunction in anthracycline-treated breast cancer: a single-centre retrospective study.

Ma J, Ma Z, Cheng Y, Li X, Song H, Wang S

Open source

DOI
10.3389/fonc.2026.1913970
Published
2026
Container
Frontiers in oncology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2026.1913970,
  title = {Galectin-9, FABP4 and pentraxin-3 are associated with myocardial dysfunction and discriminate chemotherapy-related cardiac dysfunction in anthracycline-treated breast cancer: a single-centre retrospective study.},
  author = {Ma J and Ma Z and Cheng Y and Li X and Song H and Wang S},
  year = {2026},
  journal = {Frontiers in oncology},
  doi = {10.3389/fonc.2026.1913970},
  url = {https://doi.org/10.3389/fonc.2026.1913970}
}

RIS

TY  - JOUR
TI  - Galectin-9, FABP4 and pentraxin-3 are associated with myocardial dysfunction and discriminate chemotherapy-related cardiac dysfunction in anthracycline-treated breast cancer: a single-centre retrospective study.
AU  - Ma J
AU  - Ma Z
AU  - Cheng Y
AU  - Li X
AU  - Song H
AU  - Wang S
PY  - 2026
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2026.1913970
UR  - https://doi.org/10.3389/fonc.2026.1913970
ER  - 

APA

J, M., Z, M., Y, C., X, L., H, S., & S, W. (2026). Galectin-9, FABP4 and pentraxin-3 are associated with myocardial dysfunction and discriminate chemotherapy-related cardiac dysfunction in anthracycline-treated breast cancer: a single-centre retrospective study.. Frontiers in oncology. https://doi.org/10.3389/fonc.2026.1913970

Source records